Here are the 10-Q quarterly reports from MapLight Therapeutics, Inc. (MPLT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MPLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MPLT filings page.
MapLight Therapeutics, Inc. (MPLT) reported a $172.5 million net loss for the nine months ended September 30, 2026, versus $81.6 million a year earlier. Research and development expense was $151.3 million, compared with $73.7 million; operating cash use was $131.7 million versus $91.3 million. Cash, cash equivalents and investments totaled $463.4 million at September 30, and management expects current resources to fund operations through 2028, based on its plans and assumptions.
The company completed an August 2026 private placement that generated approximately $140.1 million in net proceeds after approximately $10.0 million of placement agent fees and offering expenses. In July, it announced positive topline results from ZEPHYR, a Phase 2 trial of lead candidate ML-007C-MA for schizophrenia. MapLight intends to engage the FDA in an end-of-Phase 2 meeting to discuss a confirmatory Phase 3 trial intended, together with ZEPHYR, to support an initial NDA; planning and site identification have begun.
MapLight is also conducting VISTA, a Phase 2 study of ML-007C-MA for Alzheimer's disease psychosis, with topline results expected in the second half of 2027. The company reported no revenue to date from any source, including product sales.
MapLight Therapeutics, Inc. is a clinical-stage CNS biopharmaceutical company advancing lead candidate ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis and ML-004 for autism spectrum disorder. In July 2026 it reported positive Phase 2 schizophrenia results (ZEPHYR) and Phase 2 topline data in ASD (IRIS).
For the six months ended June 30, 2026, the company recorded a net loss of $120.9 million, compared with $52.2 million a year earlier, driven by research and development expenses of $107.1 million and general and administrative expenses of $20.9 million. Cash, cash equivalents and investments totaled $351.3 million.
In August 2026, MapLight agreed to a $150.0 million private placement of common stock and pre-funded warrants. Management states that existing cash, cash equivalents and investments, together with expected private placement proceeds, are expected to fund operations through 2028.
MapLight Therapeutics, Inc. reported a first-quarter 2026 net loss of $60.7 million, widening from $22.3 million a year earlier, as it ramped research and development spending. R&D expenses rose to $53.7 million, driven by higher clinical trial and employee-related costs, while general and administrative expenses increased to $10.8 million.
The company ended March 31, 2026 with $395.2 million in cash, cash equivalents and investments and expects this to fund operations through 2027. MapLight remains a clinical-stage, pre-revenue biopharmaceutical company advancing Phase 2 trials for ML-007C-MA in schizophrenia and Alzheimer’s disease psychosis and ML-004 in autism spectrum disorder, with topline data from ZEPHYR and IRIS expected by mid-August 2026 and from VISTA in the second half of 2027.